Background: The prognostic value of PD-L1 in predicting the treatment outcomes of EGFR-
mutant NSCLC has been reported, but clinical results remain primarily inconsistent. Whether …

Background The tumor immune microenvironment influences tumor evolution in non-small
cell lung cancer (NSCLC). Yet, the prognostic value of programmed death-ligand 1 (PD-L1) …

Background: In first/second generation EGFR-TKIs, strong PD-L1 expression contributes to
primary resistance, significantly affecting patient prognosis. The relationship between PD-L1 …

Background/Aim: Recent clinical trials have shown that immune checkpoint blockades that
target either PD-1 or PD-L1 yield remarkable responses in a subgroup of patients with non …

143 Background: The predictive value of PD-L1 score to select patients for adjuvant
immunotherapy among epidermal growth factor receptor (EGFR)-mutated non-small cell …

Aim/Background: We previously showed that PD-L1 expression may be associated with
worse survival in pts with NSCLC who undergo surgery. Data are limited on PD-L1 …

Background Epidermal growth factor receptor (EGFR) mutations are most common in
Eastern Asia, and frequencies of 30–50% have been reported. EGFR-tyrosine kinase …

Objective: Epidermal growth factor receptor (EGFR) activation was reported to upregulate
programmed death-ligand 1 (PD-L1) expression in lung cancer cells and subsequently …

Methods One-hundred and seventy patients with advanced NSCLC were explored. Paraffin-
embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was …

Background The prognostic value of PD-L1 expression and its clinical relevance of NSCLC
is controversy. The impact of PD-L1 expression as the predictive biomarker for EGFR-TKIs …